BioWorld

May 17, 2010

Pharma Outlicensing: From Opportunism to R&D Funding

A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying. Read More

Money Raised Year to Date

Savient for Sale, Ardea Bid Adds Dose: Gout on Move

German Plan: Blood in Water for Overseas Reimbursement?

Money Raised By Biotech in 2010

Week in Review

Word on the Street

FDA Approvals in April

Phase I Clinical Trials Update: April 2010

Phase II Clinical Trials Update: April 2010

Pivotal/Phase III Clinical Trials Update: April 2010

Non-U.S. Clinical Trials And Regulatory Actions: April 2010

FDA Submissions, Approvals And Other Actions: April 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...